The brain has almost no energy reserve, but its activity coordinates organismal function, a
burden that requires precise coupling between neurotransmission and energy metabolism …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Major depressive disorder (MDD) is a leading cause of disease burden worldwide. While the
incidence, symptoms and treatment of MDD all point toward major sex differences, the …

Suicide is a complex public health problem of global importance. Suicidal behaviour differs
between sexes, age groups, geographic regions, and sociopolitical settings, and variably …

Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical
and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be …

Cognitive dysfunctions, including impaired attention, learning, memory, planning and
problem solving, occur in depressive episodes, often persist during remission, predict …

An estimated 50% of depressed patients are inadequately treated by available interventions.
Even with an eventual recovery, many patients require a trial and error approach, as there …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Astroglia are a broad class of neural parenchymal cells primarily dedicated to homoeostasis
and defence of the central nervous system (CNS). Astroglia contribute to the …

Gut microbiome diversity has been strongly associated with mood-relating behaviours,
including major depressive disorder (MDD). This association stems from the recently …